Clinical trial NCT03761030: L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
Official title: Targeting Dopaminergic Mechanisms of Slowing to Improve Late Life Depression
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Major Depressive Disorder
Dysthymia
Depression
Keywords: Depressive symptoms
Cognitive problems
Antidepressant non-response
Dopamine system
Older Adults
Motor slowing
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2018-12-03
Enrollment: 51
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response. Our group and others have shown that decreased thinking speed is the central cause of functional problems in patients with LLD. Similarly, decreased walking speed is associated with depression and carries additional risk for falls, hospitalization, and death. Available evidence suggests that declining functionality in the brain's dopamine system contributes to age-related cognitive and motor slowing. The central hypothesis of this study is that by enhancing dopamine functioning in the brain and improving cognitive and motor slowing, administration of carbidopa/levodopa (L-DOPA) will improve depressive symptoms in older adults.

Detailed description: Enrolled participants were aged 60 and older with (1) a DSM 5 depressive disorder, (2) significant depressive symptoms, and (3) decreased thinking or walking speed will receive 8 weeks of treatment with L-DOPA up to 450mg. We will test whether L-DOPA increases brain dopamine release using neuroimaging and whether it speeds up thinking and walking speed. Data collected in the proposed studies may help identify a new treatment for LLD, which could have large public health ramifications given the prevalence, frequent treatment resistance, and chronicity characteristic of LLD. This project also will elucidate the neurobiology of slowing at molecular, structural, and functional levels of analysis, increasing our understanding of the interplay between these aging-associated processes and the pathophysiologic changes underlying late life neuropsychiatric disorders. Exploring patient characteristics that predict response to L-DOPA may provide useful information to guide differential therapeutics and develop personalized medicine for LLD.

Eligibility criteria: Inclusion Criteria:

1. Aged 60 years and older
2. DSM 5 non-psychotic Major Depressive Disorder, Dysthymia, or Depression Not Otherwise Specified
3. Hamilton Rating Scale for Depression (HRSD) \> 15
4. Decreased processing speed (defined as performance \> 0.5SD below age-adjusted norms on Digit Symbol Substitution Test or Trail Making Test Part A) OR decreased gait speed (defined as average walking speed over 15' course \< 1m/s)
5. Willing to and capable of providing informed consent and complying with study procedures
6. Alternative standard treatments for MDD, Dysthymia, or Depression NOS (e.g., antidepressant medication or psychotherapy) have been discussed and the individual agrees to be involved in an experimental treatment.

Exclusion Criteria:

1. Diagnosis of substance abuse or dependence (excluding Tobacco Use Disorder) within the past 12 months.
2. History of or current psychosis, psychotic disorder, mania, or bipolar disorder
3. Diagnosis of probable Alzheimer's Disease, Vascular Dementia, or Parkinson's Disease (PD)
4. Mini Mental Status Exam (MMSE) \< 25
5. HRSD ≥ 28; HRSD suicide item \> 2 or the presence of significant suicide risk as judged by clinician or Clinical Global Impressions (CGI)-Severity score of 7 at baseline.
6. Current or recent (within the past 4 weeks) treatment with antidepressants, antipsychotics, dopaminergic agents, or mood stabilizers.
7. History of allergy, hypersensitivity reaction, or severe intolerance to L-DOPA
8. Acute, severe, or unstable medical or neurological illness
9. Mobility limiting osteoarthritis of any lower extremity joints, symptomatic lumbar spine disease, mobility limiting history of joint replacement surgery, or history of spine surgery

   FOR SUBJECTS RECEIVING PET/MRI SCANS ONLY:
10. Having contraindication to MRI scanning (such as metal in body) or unable to tolerate the scanning procedures
11. History of significant radioactivity exposure (nuclear medicine studies or occupational exposure)

Primary outcomes:
measure: Change From Baseline Hamilton Rating Scale for Depression 24-Item Scale to Study Completion (8 Weeks)
timeFrame: Change from Baseline to 8 Weeks
Secondary outcomes:
measure: Digit Symbol Test
timeFrame: Change from Baseline to 8 Weeks
measure: Single Task Gait Speed
timeFrame: Change from Baseline to 8 Weeks
measure: Inventory of Depressive Symptomatology--Self Report (IDS-SR)
timeFrame: Change from Baseline to 8 Weeks
measure: Pattern Comparison Test
timeFrame: Change from Baseline to 8 Weeks
measure: Letter Comparison Test
timeFrame: Change from Baseline to 8 Weeks
Other outcomes:
Locations:
city: New York
country: United States
facility: New York State Psychiatric Institute
state: New York
Study officials:
affiliation: New York State Psychiatric Institute
name: Bret Rutherford, MD
role: PRINCIPAL_INVESTIGATOR
References: